Clinical Trials Browser

Phase 2 × HR+/HER2- Breast Cancer × Clear all

NCT07130643 2025-08-19

Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

Phase 2 Active not recruiting

HR+/HER2- Breast Cancer

NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Phase 2 Recruiting

HR+/HER2- Breast Cancer

NCT05633914 2023-02-21

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Phase 2 Unknown

HR+/HER2- Breast Cancer